Robert G. Hindes - Publications

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

Journal: The New England journal of medicine

Published: January 17, 2014

Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C.

Journal: Antiviral therapy

Published: May 08, 2013

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.

Journal: Lancet (London, England)

Published: March 19, 2013

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.

Journal: The Lancet. Infectious diseases

Published: March 19, 2013

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

Journal: The New England journal of medicine

Published: January 04, 2013

Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Published: November 30, 2012

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.

Journal: The Lancet. Infectious diseases

Published: June 21, 2012

Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation.

Journal: Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society

Published: June 19, 2012